Tracking heart muscle changes in atrial fibrillation with a smartwatch
Uses a smartwatch and heart scans to follow atrial fibrillation patients' heart muscle over time.
Plain-language title generated from the registry record
Registry title: Tulane iPredict, Prevent Study to Evaluate the Progression of Atrial Myopathy.
Key facts
- Where
- New Orleans, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 79 years old?
Source: NCT04703166, who can take part
Where in United States
- Tulane University School of MedicineNew Orleans, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tulane University School of Medicine
- Trial code
- NCT04703166
- Record updated
- 20 October 2026
- Original description
To evaluate the progression of atrial myopathy through wearable devices and cardiac imaging.Read full original descriptionShow less
Tulane iPredict, Prevent (TiPP) Study
To evaluate the progression of atrial myopathy through wearable devices and cardiac imaging.
Inclusion: Participants must meet the following criteria to be enrolled in the trial:; Participants with atrial fibrillation aged 18 to 79 years old, or; Participants aged 40 to 79 years old, at moderate or high risk for CVD as defined by the 10-year risk Atherosclerotic Cardiovascular Disease (ASCVD), a validated risk calculation tool; Participants who have access to internet/e-mail in their homes; Participants who have access to a compatible Android mobile device or compatible iOS mobile device (iPhone 4S or newer, iPad 3 or newer); Participants who are able and willing to return to the study clinic one-year following their baseline CMR for a follow-up appointment and 12-month CMR; Participants who are able to read, understand, and sign the consent form.
Exclusion: Any health-related gadolinium/MRI contraindications (e.g. allergy to gadolinium, pacemakers, Implantable Cardioverter Defibrillators (ICD's), other devices/implants contraindicated for use of MRI, etc.); Participants with renal insufficiency (Glomerular Filtration Rate (GFR) <30 mL per minute per 1.73 m2) or acute/severe renal dysfunction/disease; Participants will be excluded from enrollment if any of the following criteria are present:; Participants weighing >300 lbs. (MRI quality decreases as BMI increases); Women who are pregnant at the time of enrollment/consent. (Should a participant become pregnant during the course of the study, no CMR will be performed until 10 days, postpartum); Participants who do not have access to the internet/e-mail; Participants who do not have a compatible Android mobile device or compatible iOS mobile device (iPhone 4S or newer, iPad 3 or newer); Participants with cognitive impairments affecting their ability to be compliant with wearing and maintaining wearable devices; Participants who are unable or unwilling to return to the study clinic one-year post baseline for their follow-up appointment and CMR; Participants with cognitive impairments who are unable to give informed consent.